Abstract
Background We developed two unique machine learning (ML) models that predict risk of: 1) a major COVID-19 outbreak in the service county of a local HD population within following week, and 2) a hemodialysis (HD) patient having an undetected SARS-CoV-2 infection that is identified after following 3 or more days.
Methods We used county-level data from United States population (March 2020) and HD patient data from a network of clinics (February-May 2020) to develop two ML models. First was a county-level model that used data from general and HD populations (21 variables); outcome of a COVID-19 outbreak in a dialysis service area was defined as a clinic being located in one of the national counties with the highest growth in COVID-19 positive cases (number and people per million (ppm)) in general population during 22-28 Mar 2020. Second was a patient-level model that used HD patient data (82 variables) to predict an individual having an undetected SARS-CoV-2 infection that is identified in subsequent ≥3 days.
Results Among 1682 counties with dialysis clinics, 82 (4.9%) had a COVID-19 outbreak during 22-28 Mar 2020. Area under the receiver operating characteristic curve (AUROC) for the county-level model was 0.86 in testing dataset. Top predictor of a county experiencing an outbreak was the COVID-19 positive ppm in the general population in the prior week. In a select group (n=11,664) used to build the patient-level model, 28% of patients had COVID-19; prevalence was by design 10% in the testing dataset. AUROC for the patient-level model was 0.71 in the testing dataset. Top predictor of an HD patient having a SARS-CoV-2 infection was mean pre-HD body temperature in the prior week.
Conclusions Developed ML models appear suitable for predicting counties at risk of a COVID-19 outbreak and HD patients at risk of having an undetected SARS-CoV-2 infection.
Competing Interest Statement
CM, JWL, SC, HH, YJ, LAU, FWM are employees of Fresenius Medical Care in the Global Medical Office. KMB, EDW, IADS, KB, JLH, RJK are employees of Fresenius Medical Care North America. LN is an employee of Fresenius Medical Care Deutschland GmbH in the EMEA Medical Office. PK is an employee of Renal Research Institute, a wholly owned subsidiary of Fresenius Medical Care. IADS, KB, PK, JLH, RJK, LAU, FWM have share options/ownership in Fresenius Medical Care. PK receives honorarium from Up-To-Date and is on the Editorial Board of Blood Purification and Kidney and Blood Pressure Research. JLH has directorships in the Renal Physicians Association Board of Directors and Nephroceuticals LLC Scientific Advisory Board. FWM has directorships in the Fresenius Medical Care Management Board, Goldfinch Bio, and Vifor Fresenius Medical Care Renal Pharma. JPK has no conflicts of interest to disclose.
Funding Statement
Project and manuscript composition were supported internally by Fresenius Medical Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This analysis was performed in adherence with the Declaration of Helsinki under a protocol reviewed by New England Independent Review Board (NEIRB). This retrospective analysis was determined to be exempt and did not require consent (Needham Heights, MA, United States; NEIRB#1-17-1302368-1).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets with dialysis patient data used for this analysis are not publicly available.
